# Capital Offload-Shock

Study · id `cardio:ct-nct07756801` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07756801](<https://clinicaltrials.gov/study/NCT07756801>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07756801

Browse, organ or system: Heart  
Browse, condition area: Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 456 participants.

## Technical summary

Registry record NCT07756801. Randomized; no masking; primary purpose treatment. Start 2026-12-01 (anticipated); primary completion 2027-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 456 participants (planned count; ClinicalTrials.gov record NCT07756801, source copy `cardio:ctgov-nct07756801-2026-10-30`, retrieved 2026-10-31)
- Planned start: 2026-12-01 (anticipated) (ClinicalTrials.gov record NCT07756801, source copy `cardio:ctgov-nct07756801-2026-10-30`, retrieved 2026-10-31)
- Primary completion: 2027-09 (anticipated) (ClinicalTrials.gov record NCT07756801, source copy `cardio:ctgov-nct07756801-2026-10-30`, retrieved 2026-10-31)
- Completion: 2031-09 (anticipated) (ClinicalTrials.gov record NCT07756801, source copy `cardio:ctgov-nct07756801-2026-10-30`, retrieved 2026-10-31)
- Countries: Canada (ClinicalTrials.gov record NCT07756801, source copy `cardio:ctgov-nct07756801-2026-10-30`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07756801-2026-10-30`, retrieved 2026-10-31)

## The registry's words

- Brief title: Capital Offload-Shock
- Acronym: OFFLOAD-SHOCK
- Condition: Hypervolemia
- Condition: Cardiogenic Shock
- Condition: Renal Replacement Therapies
- Intervention (Drug): Immediate renal replacement therapy
- Lead sponsor: Ottawa Heart Institute Research Corporation
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Cardiogenic shock (`cardio:cardiogenic-shock`)
- Registry lists this organization as the lead sponsor: Ottawa Heart Institute Research Corporation (`cardio:org-ottawa-heart-institute-research-corporation`)

## Provenance

Content hash: ff85e4dcbf7f2dc8dd837e387be96fe1f3e77c69dfdeb8f050ede663cb15e3d1
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
